CIB0.DE vs. NBTK.DE

Last updated Jun 5, 2026

CIB0.DE (VanEck Bionic Engineering UCITS ETF A) and NBTK.DE (Invesco Nasdaq Biotech UCITS ETF) are both Health & Biotech Equities funds - CIB0.DE tracks the MVIS Global Bionic Healthcare ESG while NBTK.DE tracks the Nasdaq Biotechnology. Both are passively managed. Over the past 3 years, CIB0.DE returned -8.20%/yr vs 9.94%/yr for NBTK.DE. At a 0.49 correlation, their price movements are largely independent. CIB0.DE charges 0.55%/yr vs 0.40%/yr for NBTK.DE.

Performance

CIB0.DE vs. NBTK.DE - Performance Comparison

The chart below illustrates the hypothetical performance of a €10,000 investment in VanEck Bionic Engineering UCITS ETF A (CIB0.DE) and Invesco Nasdaq Biotech UCITS ETF (NBTK.DE). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, CIB0.DE achieves a -14.18% return, which is significantly lower than NBTK.DE's 4.27% return.

CIB0.DE

• 1D: 3.05%
• 1M: 1.36%
• YTD: -14.18%
• 6M: -17.46%
• 1Y: -15.36%
• 3Y*: -8.20%
• 5Y*: —
• 10Y*: —

NBTK.DE

• 1D: 2.92%
• 1M: 0.38%
• YTD: 4.27%
• 6M: 3.76%
• 1Y: 39.20%
• 3Y*: 9.94%
• 5Y*: 5.63%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

CIB0.DE vs. NBTK.DE - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022
CIB0.DE VanEck Bionic Engineering UCITS ETF A	-14.18%	-10.00%	5.16%	2.09%	-1.65%
NBTK.DE Invesco Nasdaq Biotech UCITS ETF	4.27%	18.60%	4.57%	2.51%	-3.59%

Correlation

The correlation between CIB0.DE and NBTK.DE is 0.43, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.43
Correlation (3Y) Calculated over the trailing 3-year period	0.47
Correlation (All Time) Calculated using the full available price history since Dec 8, 2022	0.49

Return for Risk

CIB0.DE vs. NBTK.DE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CIB0.DE

CIB0.DE Risk / Return Rank: 2
CIB0.DE Sharpe Ratio Rank: 2
CIB0.DE Sortino Ratio Rank: 3
CIB0.DE Omega Ratio Rank: 3
CIB0.DE Calmar Ratio Rank: 4
CIB0.DE Martin Ratio Rank: 0

NBTK.DE

NBTK.DE Risk / Return Rank: 71
NBTK.DE Sharpe Ratio Rank: 61
NBTK.DE Sortino Ratio Rank: 63
NBTK.DE Omega Ratio Rank: 56
NBTK.DE Calmar Ratio Rank: 92
NBTK.DE Martin Ratio Rank: 84

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CIB0.DE vs. NBTK.DE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for VanEck Bionic Engineering UCITS ETF A (CIB0.DE) and Invesco Nasdaq Biotech UCITS ETF (NBTK.DE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CIB0.DE	NBTK.DE	Difference
Sharpe ratio: Return per unit of total volatility	-0.89	2.03	-2.92
Sortino ratio: Return per unit of downside risk	-1.20	2.87	-4.07
Omega ratio: Gain probability vs. loss probability	0.87	1.34	-0.47
Calmar ratio: Return relative to maximum drawdown	-0.65	6.16	-6.81
Martin ratio: Return relative to average drawdown	-1.67	17.06	-18.73
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

CIB0.DE vs. NBTK.DE - Sharpe Ratio Comparison

The current CIB0.DE Sharpe Ratio is -0.89, which is lower than the NBTK.DE Sharpe Ratio of 2.03. The chart below compares the historical Sharpe Ratios of CIB0.DE and NBTK.DE, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	CIB0.DE	NBTK.DE	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.89	2.03	-2.92
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.27	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.31	0.42	-0.73

Drawdowns

CIB0.DE vs. NBTK.DE - Drawdown Comparison

The maximum CIB0.DE drawdown since its inception was -32.60%, which is greater than NBTK.DE's maximum drawdown of -30.99%. Use the drawdown chart below to compare losses from any high point for CIB0.DE and NBTK.DE.

Drawdown Indicators

	CIB0.DE	NBTK.DE	Difference
Max Drawdown Largest peak-to-trough decline	-32.60%	-30.99%	-1.61%
Max Drawdown (1Y) Largest decline over 1 year	-23.47%	-6.24%	-17.23%
Max Drawdown (3Y) Largest decline over 3 years	-32.60%	-29.35%	-3.25%
Max Drawdown (5Y) Largest decline over 5 years	—	-30.99%	—
Current Drawdown Current decline from peak	-28.26%	-1.44%	-26.82%
Average Drawdown Average peak-to-trough decline	-10.72%	-10.62%	-0.10%
Ulcer Index Depth and duration of drawdowns from previous peaks	9.08%	2.26%	+6.82%

Volatility

CIB0.DE vs. NBTK.DE - Volatility Comparison

VanEck Bionic Engineering UCITS ETF A (CIB0.DE) and Invesco Nasdaq Biotech UCITS ETF (NBTK.DE) have volatilities of 6.42% and 6.41%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CIB0.DE	NBTK.DE	Difference
Volatility (1M) Calculated over the trailing 1-month period	6.42%	6.41%	+0.01%
Volatility (6M) Calculated over the trailing 6-month period	12.62%	14.11%	-1.49%
Volatility (1Y) Calculated over the trailing 1-year period	17.03%	19.00%	-1.97%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	17.95%	20.30%	-2.35%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	17.95%	22.05%	-4.10%

CIB0.DE vs. NBTK.DE - Expense Ratio Comparison

CIB0.DE has a 0.55% expense ratio, which is higher than NBTK.DE's 0.40% expense ratio.

Dividends

CIB0.DE vs. NBTK.DE - Dividend Comparison

Neither CIB0.DE nor NBTK.DE has paid dividends to shareholders.

Tickers have no history of dividend payments

Frequently Asked Questions

Can I hold both CIB0.DE and NBTK.DE in my portfolio?

CIB0.DE and NBTK.DE have a correlation of 0.43, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which ETF is better, CIB0.DE or NBTK.DE?

On fees, NBTK.DE is cheaper at 0.40% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, CIB0.DE or NBTK.DE?

NBTK.DE is cheaper with a 0.40% expense ratio, compared with 0.55% for CIB0.DE.

What is the main difference between CIB0.DE and NBTK.DE?

CIB0.DE tracks MVIS Global Bionic Healthcare ESG, while NBTK.DE tracks Nasdaq Biotechnology. They also come from different issuers: VanEck and Invesco. Their fees differ too: 0.55% for CIB0.DE and 0.40% for NBTK.DE.